BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
Year: 2017
Type: article
Abstract: The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design.
Institutions: University of Nebraska Medical Center, Inserm, Centre de Recherches en Cancérologie de Toulouse, Roswell Park Comprehensive Cancer Center, Dana-Farber Cancer Institute, Navarre Institute of Health Research, Clinica Universidad de Navarra, Medical College of Wisconsin, Levine Cancer Institute, Universitätsklinikum Tübingen
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Awards: Ancillary Studies in Clinical Trials - PRIMeR, Determining the mutational landscape of circulating multiple myeloma cells, G777363952, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc., G911192202
OpenAlex ID: W2773882070